Tirzepatide vs Survodutide: 20.9% vs 18.7% Weight Loss Compared

Tirzepatide and survodutide both get called "dual agonists," and that shared label makes them sound like close cousins. They are not. Tirzepatide keeps both incretin receptors: it activates GLP-1 and adds GIP, glucose-dependent insulinotropic polypeptide, in a single molecule. Survodutide takes a different second receptor entirely: it activates GLP-1 and adds glucagon, the hormone more commonly associated with raising blood glucose than lowering weight. Same category name, different chemistry, different evidence base.

This is an evidence-first comparison: the trial figures, the mechanism, tolerability and dosing, where each compound sits in development and regulatory status, and who each is actually built for. Tirzepatide is a research compound we sell; survodutide is discussed here purely for comparison and is not something Modern Bio offers. Everything below reports what the published clinical literature describes; none of it is medical advice.

Tirzepatide vs survodutide at a glance

The short version: tirzepatide has the higher weight-loss number, the second-receptor advantage that made the drug class-defining, and it is already on the market. Survodutide has a leaner but genuinely different mechanism and a liver-disease dataset built on biopsy evidence. The rest of this article is what sits behind each of those rows.

Which produces more weight loss: the head-to-head numbers

The headline comparison is the one everyone searches for, so start there. The standing caveat matters more here than in most comparisons on this site: tirzepatide's figures come from a completed Phase 3 program, while survodutide's come from Phase 2. No trial has randomized people directly to one compound or the other, and the two programs are not even at the same stage of development.

Tirzepatide's top-dose mean, 20.9%, tops survodutide's top-dose mean of about 18.7%, though the trials ran at different durations, 72 weeks against 46, and different phases of development. ^{[1] [2]} That duration gap cuts both ways: it gives tirzepatide more time to reach its ceiling, but it also means survodutide's number was read earlier in its response curve, when levels may not yet have plateaued. The honest framing is a strong cross-trial signal, not causal proof: different sites, different populations, different titration schedules, and a Phase 3 versus Phase 2 comparison that is not apples to apples on rigor alone.

Two different "dual agonists": GIP vs glucagon

The efficacy comparison only makes sense once the mechanism is clear, because "dual agonist" hides a real fork in the road.

Tirzepatide keeps both incretin receptors: it activates GLP-1 for appetite suppression and glucose handling, then adds GIP, which appears to amplify what GLP-1 activation already does rather than act as an independent pathway of its own. ^[3] That amplification is the leading mechanistic explanation for why tirzepatide reached a higher ceiling than the first generation of single-receptor GLP-1 drugs.

Survodutide takes the opposite second receptor. It keeps the same GLP-1 foundation but pairs it with glucagon instead of GIP. On its own, glucagon raises blood glucose, which sounds counterproductive in a metabolic drug. Paired with GLP-1 coverage, though, its useful contribution, increased energy expenditure and lipid mobilization, is retained while the GLP-1 arm offsets the glycemic penalty. ^[2] That is a genuinely different mechanistic bet than tirzepatide's: one adds an amplifier to the incretin system, the other adds an energy-expenditure lever from outside it entirely. If a triple agonist that combines both approaches is also in your comparison set, retatrutide vs survodutide covers a compound that keeps GIP and adds glucagon on top.

So the two most prominent dual agonists in the weight-loss category share only the GLP-1 backbone. A search for one "dual agonist" comparison does not automatically transfer to the other, because the second receptor, and what it does, is not the same. The full receptor-level breakdown of tirzepatide's mechanism is in how peptides work: receptor mechanisms.

Side effects and tolerability: how the profiles compare

Both compounds share the same dominant side-effect story, because both are built on the same GLP-1 foundation, and each also carries an effect specific to its second receptor.

The gastrointestinal effects are the shared headline: nausea, diarrhea, constipation, and reduced appetite, all dose-dependent and concentrated during dose escalation, then easing once the dose stabilizes. ^{[1] [2]} This is the class signature that any GLP-1-based compound carries, tirzepatide and survodutide included, and it is why both are titrated gradually rather than started at target dose.

Where the two diverge is the second receptor. Survodutide's glucagon arm reported a modest increase in heart rate in its Phase 2 program, a finding that tracks with glucagon's known cardiac effects and is not something tirzepatide's GIP arm produces. ^[2] Tirzepatide's own side-effect profile, including its comparatively lower reported nausea rate relative to single-receptor GLP-1 drugs, is covered in depth in the tirzepatide side effects guide.

Why both cause GI effects, and why they fade

The gastrointestinal effects are a direct extension of the shared GLP-1 mechanism, not an incidental side issue. GLP-1 receptor activation slows gastric emptying, which is part of how both compounds reduce appetite, and that same slowing produces nausea when exposure changes too quickly. That is why symptoms are worst during dose escalation, when plasma levels are climbing fastest, and why they settle once the dose holds steady. Both trial protocols titrate stepwise over several weeks specifically to give the gut time to adapt at each level. ^{[1] [2]} None of this is dosing advice; it is the trial-reported rationale for why both escalation schedules look the way they do.

Dosing and titration: how the cadence compares

On the surface these two are close to identical to run: both are once-weekly subcutaneous compounds with multi-week stepwise titration. The differences are in the numbers, and the numbers do not translate across compounds.

The milligram numbers are not comparable across compounds: potency per milligram differs, so tirzepatide's 15 mg and survodutide's 4.8 mg are not measuring the same dose intensity. What matters is the mean effect at each compound's own top studied dose, which is the column in the weight-loss table above.

Both cadences work because both molecules are engineered for extended action that supports weekly dosing. Tirzepatide's roughly 5-day half-life is well characterized, ^[3] and the practical consequence is the same for both compounds: plasma levels build over weeks and reach a stable state before the full effect shows up, which is exactly why trial endpoints are read at 46 and 72 weeks rather than early. A quiet first month is not a sign either compound is failing; it reflects levels still climbing toward steady state.

Development stage and approval: the biggest practical difference

Efficacy numbers get most of the attention, but the gap that matters most in practice is regulatory status, and here the two compounds are not close.

Tirzepatide has already cleared the full regulatory bar: it is FDA-approved and sold as Mounjaro for type 2 diabetes and Zepbound for chronic weight management, on top of existing in the research-compound market at a different price point. Survodutide has not: it completed Phase 2 in both obesity and MASH and is now running Phase 3, but no indication has reached approval yet. That difference in maturity is the reason tirzepatide's evidence base, described in detail in the complete tirzepatide guide, is deeper than survodutide's on essentially every axis except one, discussed next.

Beyond the scale: survodutide's liver-disease program

The one area where survodutide's evidence is arguably more targeted than tirzepatide's is the liver.

Survodutide was studied directly in MASH, metabolic dysfunction-associated steatohepatitis, the serious inflammatory form of fatty liver disease, and its Phase 2 MASH trial reported high rates of histological improvement without worsening of fibrosis compared with placebo. ^[4] That is a meaningful distinction: rather than inferring a liver benefit from an imaging endpoint, survodutide's program measured it on biopsy in a disease population, which is a higher evidentiary bar than most metabolic-compound liver claims clear.

Tirzepatide has not run an equivalent dedicated liver-disease program with biopsy endpoints in its published data to date. That does not mean it has no liver effect, glucose and weight improvements broadly track with metabolic liver health, but it does mean the evidence is comparatively less developed on that specific axis than survodutide's purpose-built dataset. For a research question centered specifically on liver disease rather than weight, that gap is worth weighing against tirzepatide's larger, longer, and regulatorily complete weight-loss program.

Who each is right for

Neither compound is universally the better choice. They sit at different points on a maturity-versus-mechanism map.

Put plainly: tirzepatide is the mature, regulatorily complete option with the larger and longer-running evidence base. Survodutide is the earlier-stage compound whose distinguishing asset is not a bigger number but a different mechanism and a dedicated liver-disease dataset. For a research program built around the most complete available evidence, tirzepatide is the stronger draw. For a program specifically interested in the GLP-1/glucagon pairing or liver-disease measurement, survodutide is the more targeted tool, with the caveat that its full Phase 3 results are still pending.

If retatrutide, which combines both the GIP and glucagon receptors in one molecule, is also in the comparison set, retatrutide vs survodutide extends this same framework to the triple-agonist frontier.

The bottom line

On the numbers and the regulatory record, tirzepatide leads: 20.9% versus roughly 18.7% mean weight loss, at a longer duration, backed by a completed Phase 3 program and FDA approval that survodutide does not yet have. ^{[1] [2]} But the two are not simply "better and worse" versions of the same drug; they are different mechanistic bets, GIP versus glucagon, and survodutide's dedicated MASH program gives the liver-disease question its clearest evidence in this pairing. ^[4] The comparison is cross-trial and cross-phase, not head-to-head, and survodutide remains investigational. For the full tirzepatide picture, see the complete tirzepatide guide.

For research and educational purposes only. Not medical advice. Trial figures describe published clinical studies; cross-compound comparisons are drawn from separate trials at different development phases, not a head-to-head study. Tirzepatide is FDA-approved and sold under the brand names Mounjaro and Zepbound; survodutide is investigational and is not approved for human use.